Paragangliomas are neuroendocrine tumors frequently associated with mutations in RET, NF1, VHL, and succinate dehydrogenase (SDHx) genes. Methylome analysis of a large paraganglioma cohort identified three stable clusters, associated with distinct clinical features and mutational status. SDHx-related tumors displayed a hypermethylator phenotype, associated with downregulation of key genes involved in neuroendocrine differentiation. Succinate accumulation in SDH-deficient mouse chromaffin cells led to DNA hypermethylation by inhibition of 2-OG-dependent histone and DNA demethylases and established a migratory phenotype reversed by decitabine treatment. Epigenetic silencing was particularly severe in SDHB-mutated tumors, potentially explaining their malignancy. Finally, inactivating FH mutations were identified in the only hypermethylated tumor without SDHx mutations. These findings emphasize the interplay between the Krebs cycle, epigenomic changes, and cancer.
INTRODUCTION
Paragangliomas (PGL) are neural crest-derived tumors that arise from parasympathetic ganglia of the head and neck region or from sympathetic ganglia located in the thorax, abdomen, or pelvis. These tumors may develop in the adrenal medulla, in which case they are called pheochromocytomas (PCC) (Lenders et al., 2005) . There has been extensive genetic characterization
Significance
Unexpected links between epigenetic and genetic alterations were recently identified with the demonstration that IDH mutations impair DNA demethylation in gliomas. Mutations affecting succinate dehydrogenase (SDH), another tricarboxylic acid cycle enzyme, have been identified in several cancers and are particularly frequent in paragangliomas. With this genome-wide analysis of DNA methylation changes in a large paraganglioma cohort, we demonstrate that SDHx, and particularly SDHB-related metastatic tumors, display a hypermethylator phenotype, associated with downregulation of key genes implicated in chromaffin cell differentiation. These findings explain the oncogenic effect of SDH inactivation and the invasiveness of SDHB-mutated tumors and raise the possibility of innovative epigenetic therapies involving DNA demethylating agents for these cancers.
of PGL/PCC. At least 30% of patients harbor a germline mutation in one of the ten identified susceptibility genes : RET, NF1, VHL, SDHAF2, TMEM127, or MAX, and in genes encoding the four subunits of succinate dehydrogenase (SDHA, SDHB, SDHC, or SDHD, referred to as SDHx genes). Integrated genomic analysis of the largest available cohort of PGL/PCC, recruited by the French COMETE network, identified homogeneous molecular subgroups associated with susceptibility genes (Burnichon et al., 2011) and showed that a large proportion of sporadic PGL/PCC carry a somatic mutation in VHL, RET, NF1, MAX, or HIF2A genes (Burnichon et al., 2011 , 2012a , 2012b Favier et al., 2012) . Overall, 60% of cases harbor a somatic or germline mutation in a known predisposing gene.
Various important issues remain to be unraveled, including the oncogenic role of SDHx mutations. Succinate dehydrogenase was the first mitochondrial enzyme to be identified as a tumor suppressor in familial PGL (Baysal et al., 2000) . Its inactivation also predisposes to renal cell carcinoma (Ricketts et al., 2008) and gastrointestinal stromal tumors (Janeway et al., 2011) . To date, the only mechanism linking SDH to cancer involves hypoxia-inducible factors (HIFs) (Dahia et al., 2005; GimenezRoqueplo et al., 2001) . SDH dysfunction results in the accumulation of succinate (Pollard et al., 2005) , its tricarboxylic acid cycle (TCA) substrate, which acts as a competitive inhibitor of the 2-oxoglutarate (2-OG)-dependent HIF prolyl-hydroxylases (Bri-è re et al., Selak et al., 2005) . This stabilizes HIF-alpha and activates genes that facilitate angiogenesis and anaerobic metabolism. However, the exact role of HIFs in oncogenesis remains unclear (Young and Simon, 2012) . Understanding SDH-related tumorigenesis is crucial, because the presence of a germline mutation in the SDHB gene is a major risk factor of malignancy and of poor prognosis. Around 40% of all patients with a metastatic form of the disease harbor an SDHB mutation (Pasini and Stratakis, 2009) . SDHB-mutation carriers have a 19-fold higher risk of developing a metastatic disease (Gimenez-Roqueplo et al., 2003) and shorter survival than patients with a malignant PGL/PCC but without SDHB mutations (Amar et al., 2007) .
DNA methylation changes are hallmarks of human cancers (Hanahan and Weinberg, 2011) . Cancer cells often display overall DNA hypomethylation and hypermethylation of promoter CpG islands, resulting in the transcriptional silencing of tumor suppressor genes (Jones and Baylin, 2007) . Unlike genetic mutations, DNA methylation is a reversible process and is thus a promising target for drug development (Rodríguez-Paredes and Esteller, 2011) . These epigenetic features are also useful as biomarkers for early detection of cancer in blood samples, for prognosis, or for prediction of response to treatment (Laird, 2003) . Genome-scale DNA methylation profiling has allowed the identification of epigenetic subtypes in several cancers (Hinoue et al., 2012; Noushmehr et al., 2010) . A CpG island methylator phenotype (CIMP), characterized by the concerted hypermethylation of a large number of genes, was initially described in colorectal cancer (Toyota et al., 1999) and was recently identified in glioma (G-CIMP; Noushmehr et al., 2010) . In glioma, the G-CIMP phenotype is associated with gain-of-function mutations in IDH1 and IDH2 that confer to these enzymes a neomorphic capacity to convert a-ketoglutarate (a-KG, or 2-OG) into the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG acts as a competitive inhibitor of 2-OG-dependent dioxygenases, including histone demethylases and the TET family of 5-methylcytosine (5-mC) hydroxylases, leading to genome-wide DNA methylation alterations (Xu et al., 2011) . Succinate also can inhibit these enzymes in vitro, suggesting that SDH-related tumorigenesis may involve epigenetic alterations (Xiao et al., 2012) . However, DNA methylation changes of only a limited number of genes have been investigated so far in PGL/PCC (Geli et al., 2008) and have not been compared with expression data or mutational status.
Here, we report the genome-scale methylome and transcriptome profiling of the well-annotated COMETE cohort and investigate the relationship between SDHx mutations and DNA methylation changes in a mouse model of SDH-related paraganglioma.
RESULTS

DNA Methylation-Based Classification of Pheochromocytomas and Paragangliomas
We determined DNA methylation profiles of 145 pheochromocytomas and paragangliomas using the Illumina Infinium HM27 DNA methylation assay, which assesses the degree of methylation of 27,578 CpG sites in promoter regions of 14,495 protein-coding genes (Bibikova et al., 2009) . Gene expression was previously characterized in most of these samples (Burnichon et al., 2011) , and the mutation status of the main genes predisposing to PGL/PCC (SDHx, VHL, NF1, RET, TMEM127, and MAX) was analyzed (Table S1 available online). As previously described (Hinoue et al., 2012) , we excluded probes that might be unreliable and probes designed for sequences on sex chromosomes. We selected the 10% most variant probes, according to the standard deviation of the beta values, and performed consensus clustering (Monti et al., 2003) to identify DNA methylation clusters. The optimal classification defined three tumor subgroups ( Figure 1A ; Figure S1 ). Tumors of the M1 cluster displayed concerted hypermethylation at a large number of loci ( Figure 1B) , reminiscent of the CpG island methylator phenotypes described in colorectal cancer and glioblastoma.
For comparison, we applied a second clustering approach, the recursively partitioned mixture model (RPMM; Houseman et al., 2008) , to our data set. Cluster assignments using consensus clustering and RPMM were strongly correlated (p = 9.7 3 10 À39 ), with the two methods agreeing on cluster membership for 90% (130/145) of the tumors ( Figure S1F ). In particular, the M1 cluster was similarly identified by the RPMM approach, with only 1/17 samples misclassified. We based our subsequent analyses on the consensus clusters, which showed better association with clinical criteria. We next sought to characterize DNA methylation changes in each cluster. We analyzed probes located within and outside CpG islands separately (Takai and Jones, 2002) . Most CpGs within CpG islands are demethylated in normal tissues and undergo hypermethylation in tumors (Jones and Baylin, 2007) , whereas CpGs outside CpG islands are mostly highly methylated in normal tissues and undergo loss of DNA methylation in cancers (Feinberg and Vogelstein, 1983) . Because of the difficulty in obtaining samples of normal adrenal medulla, only three normal controls were available, hence the comparison with tumor clusters had limited power. After FDR adjustment,
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Hypermethylator Phenotype in SDH-Related PGL/PCC significant methylation differences between tumors and normal controls were only detected in cluster M1 (1,015 probes with FDR-adjusted p < 0.05). However, the number of significant tests (p < 0.01) was substantially higher than expected by chance in each cluster (8.7%, 4.8%, and 6.4% in M1, M2, and M3, respectively) . Cluster M1 tumors displayed a hypermethylator phenotype, characterized by high methylation levels at a large number of CpG sites, both within (7.2% of probes, p < 0.01; Figure 1C ; Table S2 ) and outside (7.0%) CpG islands. Clusters M2 and M3 did not display substantial hypermethylation within CpG islands, but a strong hypomethylation outside CpG islands was observed in both clusters, particularly in cluster M3 (5.9% of probes hypomethylated in M2, 9.6% in M3).
Association with Genomic and Clinical Features DNA methylation clusters were highly associated with mutational status (p = 3.3 3 10
À33
) and gene expression clusters (p = 1.3 3 10 À41 ) ( Figure 1B ; Table 1 ). In particular, the hypermethylator Table S1 ) identifies three stable DNA methylation clusters. The consensus matrix represents the similarity between tumors. Consensus index values range from zero (highly dissimilar profiles, white) to one (highly similar profiles, dark blue). Samples are ordered on the x and y axes by the consensus clustering, which is depicted atop the heatmap. See also Figure S1 . (B) Heatmap representation of DNA methylation profiles. The degree of DNA methylation (beta value) for each probe (row) in each sample (column) is represented with a color scale (dark blue, nonmethylated; yellow, methylated). Tumors are ordered by methylation cluster. Probes are arranged by similarity, as assessed by hierarchical cluster analysis. The mutation status of the main genes predisposing to PGL/PCC (SDHx, VHL, NF1, and RET) is indicated above the heatmap, together with expression cluster memberships as determined in a previous study (Burnichon et al., 2011) . (C) Scatterplots comparing methylation levels between tumor subgroups and normal adrenal medulla controls are shown for probes located within (top) or outside (bottom) CpG islands (Takai-Jones definition [Takai and Jones, 2002] phenotype was strongly associated with SDHx mutations. In cluster M1, 16/17 tumors were SDH-related (1 SDHA, 11 SDHB, 1 SDHC, and 3 SDHD germline mutations), and one was sporadic. Cluster M2 included 13/21 VHL-related tumors and one sporadic tumor. All RET and NF1-related samples were members of cluster M3, together with the remaining sporadic and VHL-mutated samples. Clusters M1 and M2 corresponded to the previously described C1A (SDHx-related) and C1B (VHL-related) expression clusters (Burnichon et al., 2011) , and the M3 cluster comprised all tumors of the C2 (RET/NF1-related) expression cluster, plus eight tumors from the C1B group. Age at diagnosis and histology, which are known to be associated with mutational status (Amar et al., 2005; Neumann et al., 2002) , differed significantly between DNA methylation clusters (p = 1.8 3 10 À7 and p = 1.5 3 10 À9 , respectively). The median age at diagnosis was younger for clusters M1 (32 years) and M2 (25.5 years) than for cluster M3 (47 years), and cluster M1 was enriched in paragangliomas (56% versus % 7% in clusters M2 and M3). Note that only SDH-related paragangliomas displayed a hypermethylator phenotype. Hypermethylation is thus specifically associated with SDHx mutations, rather than a characteristic of extra-adrenal tumors. Methylation clusters were significantly associated with both metastasis-free survival (MFS, p = 6.2 3 10 À8 ) and overall survival (OS, p = 0.0013), with the prognosis being much worse for M1 tumors than M2 and M3 tumors ( Figure 1D ). However, the presence of an SDHB mutation predicted prognosis more significantly than methylation cluster membership in our series (p = 8.9 3 10 À10 and p = 8.2 3 10 À6 for MFS and OS, respectively).
Sdhb Knockout in Mouse Chromaffin Cells Establishes a Hypermethylator Phenotype and Promotes Cell Migration
To investigate the mechanisms linking SDH deficiency with methylation, we generated an immortalized mouse chromaffin cell (imCC) line harboring a complete defect in SDH. We created genetically modified mice in which the endogenous Sdhb exon 2 is flanked by LoxP sites, isolated chromaffin cells from their adrenal medulla, and deleted Sdhb by Cre-mediated recombination ( Figure 2A ). Suppression of exon 2 leads to a premature stop codon and to the predicted translation of a truncated 33 aminoacids protein, instead of the 283 amino-acids wild-type (WT) SDHB protein. Two independent SdhbÀ/À clones were studied (c6 and c8). As previously reported for human tumors van Nederveen et al., 2009) , Sdhb-deficient cells completely lost SDHB protein production but had normal SDHA levels ( Figure S2A ). They displayed a selective loss of SDH/succinate cytochrome c reductase (SCCR) activity (Figures 2B, S2B, and S2C), accompanied by large increases in both intracellular ( Figure 2C ) and secreted ( Figure S2D ) succinate levels and abnormally small amounts of the following organic acids (fumarate and malate) produced by the TCA cycle. Expression and nuclear translocation of HIF2a were also higher than in controls (Figures S2E). 
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Hypermethylator Phenotype in SDH-Related PGL/PCC We used reduced representation bisulfite sequencing (RRBS) (Meissner et al., 2005) to examine base-pair resolution DNA methylation patterns in two samples of WT cells and in both SdhbÀ/À clones. We obtained more than 15 million high-quality aligned reads per sample, yielding quantitative DNA methylation data for 1,530,785 CpG dinucleotides (coverage R 10 reads in each sample). Hierarchical clustering identified two clusters corresponding to WT and SdhbÀ/À cells ( Figure 2D ). Like SDHx-related tumors, Sdhb-deficient cells displayed a widespread hypermethylation both within and outside CpG islands ( Figure 2E ). We obtained DNA methylation rates with more than ten individual CpG measurements for 78% of CpG islands (n = 12,503). CpG island methylation rates were highly correlated between the two WT samples and between the two SdhbÀ/À clones ( Figure S2F ). By contrast, 3,357 CpG islands were significantly hypermethylated, and 242 were significantly hypomethylated in SdhbÀ/À clones as compared to WT cells (FDRadjusted p < 0.05 and absolute methylation difference > 5%) ( Figure S2G ). Genes hypermethylated in Sdhb-deficient imCCs significantly overlapped those hypermethylated in SDH-related PGL/PCC (p = 3.2 3 10 À170 ), with 1,014 genes in common (Figure 2F ; Table S3 ).
Although SDH-deficiency led to a mean 2-fold decrease in growth rate ( Figure S2H ), SdhbÀ/À cells had marked increased migration capacities as assessed in a wound healing scratch assay ( Figure 2G ). These characteristics are consistent with the known specificities of SDHB-related PGL/PCC, which are not associated with increased proliferation but are associated with invasiveness. To investigate the role of DNA methylation in this phenotype, we treated SdhbÀ/À cells for 72hr with low (10 nM) or higher (5 mM) doses of 5-Aza-2 0 -deoxycytidine (decitabine or DAC), an epigenetic modifier that inhibits DNA methyltransferase activity. High doses induced cytotoxicity in all cell types (from 10% to 25% of cell death after 3 days), which was markedly reduced at low doses (cell death <8%). After drug withdrawal, the effect of DAC was assessed on cell proliferation and migration. We observed a dose-dependant blockade of cell growth in both WT and SdhbÀ/À cells ( Figure S2H ). In contrast, an inhibition of collective cell migration was specifically observed in SDH-deficient cells, but not in WT cells ( Figure 2H ).
SDH-Deficient Chromaffin Cells Display Increased 5-mC/5-hmC Ratio and Histone Methylation
Tet-mediated conversion of 5-mC to 5-hmC was evaluated by flow cytometry and immunofluorescence analyses: there was more 5-mC in SdhbÀ/À than the WT imCCs ( Figures 3A and  3B ). This effect was reversed by the addition of 2-OG to the culture medium, which also led to an increase in 5-hmC staining of SdhbÀ/À cells ( Figure S3A ). The methylation of lysines 9 and 27 of histone 3 was then assessed by western blotting. Loss of Sdhb increased H3K9me3, H3K27me2, and H3K27me3 levels ( Figure 3C , quantified in Figure S3B ). As both H3K9 and H3K27 methylation are closely linked with DNA methylation (Cedar and Bergman, 2009 ), these effects on histone methylation may contribute to the establishment of the hypermethylator phenotype.
To confirm the inhibition of oxidative demethylation by succinate in human PGL/PCC, we first measured succinate and fumarate concentrations in a subset of tumor samples and confirmed a mean 100-fold increase in succinate levels in SDHx-versus non-SDHx-mutated PGL/PCC (Table S4) . We next used immunohistochemistry to quantify 5-mC and 5-hmC, as well as H3K9me3 and H3K27me3, in 39 paraffin-embedded tumor samples with various genetic backgrounds. All (16/16) SDHxmutated tumors had low 5-hmC levels, whereas 70% (16/23) of non-SDH samples had high levels of 5-hmC ( Figure 3D ; Table  S5 ). Similarly, 81% of SDH-related PGL/PCC displayed abundant H3K27me3, whereas 43% of non-SDH tumors displayed low H3K27me3 levels ( Figure 3E ; Table S5 ). Succinate inhibition of oxidative demethylation by TET proteins and Jumonji domaincontaining histone demethylases may thus be the mechanism responsible for the accumulation of DNA methylation in SDHdeficient tumors.
Transcriptional Changes Associated with the Hypermethylator Phenotype
To better understand the impact of DNA hypermethylation in tumors of the M1 cluster, we examined the relationship between methylation and expression changes in these tumors. Principal component analysis indicated that the transcriptome differed between the DNA methylation subgroups ( Figure 4A ), consistent with the strong association between methylation and expression clusters. Of the 7,136 CpG sites that were differently methylated in M1 and non-M1 tumors (FDR-adjusted p < 0.05), 6,850 (96%) were hypermethylated in M1 tumors, resulting in a highly asymmetric volcano plot ( Figure 4B ). The transcriptome data, available for 134/145 samples, revealed a similar asymmetry ( Figure 4C ), with 623 genes significantly downregulated (FDRadjusted p < 0.05) and 356 genes significantly upregulated in cluster M1 (Table S6) . Integrated transcriptome and methylome analysis revealed that 11.5% of genes with significant hypermethylation in M1 tumors (FDR-adjusted p < 0.05 and beta value difference >0.1) also showed more than a 2-fold reduction in gene expression and that the mean shift in expression values correlated with the amplitude of the methylation difference (Figure 4D ). To gain a more comprehensive view of DNA methylation changes in M1 tumors, we reanalyzed 22 tumors (ten M1, two M2, and ten M3) using the Illumina Infinium 450K assay, which assesses the methylation levels of more than 485,000 CpG sites. Using probes present on both the 27K and 450K arrays, we verified that the beta value differences between M1 and non-M1 tumors were consistent in the two data sets (mean absolute difference = 0.023). Overall, we identified 4,663 genes with significant hypermethylation of their promoter CpG islands (Table S7) . The overlap between the lists of hypermethylated and downregulated genes was highly significant (p = 1.5 3 10 À7 ), with 191
genes showing both significant CpG island hypermethylation and significant downregulation in M1 tumors (Table S8) . Gene ontology analysis of this set of genes showed a significant enrichment in terms associated with neuroendocrine differentiation (Table S9) . Several genes are associated with catecholamine metabolic process [PNMT ( Figure S4 ), DRD2, and SULT1A1], transport (SLC6A2), or secretion (NPY); RET and NRP2 are implicated in the differentiation of neural-crest cells. RBP1 is a tumor suppressor known to be epigenetically silenced in several cancers (Esteller et al., 2002) . Downregulation of SPOCK2, an inhibitor of matrix-metalloproteases, of KRT19 (Figure S4) , a key marker of the epithelial-to-mesenchymal transition 
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Hypermethylator Phenotype in SDH-Related PGL/PCC (EMT) and of DNAJA4, recently shown to be a metastasis suppressor gene (Pencheva et al., 2012) , may participate to the invasive phenotype of SDH-deficient cells. These findings indicate that methylome remodeling results in major transcriptional abnormalities in SDH-related tumors, directly associated with their phenotypic characteristics.
Exome Sequencing of the Only Hypermethylated Sample without SDHx Mutation Identified Inactivating Mutations in the FH Gene A single tumor in our data set (HS_121) carried no SDHx mutation but displayed a hypermethylator phenotype ( Figure 1B ) as well as both low 5-hmC and high H3K9 and H3K27 methylation (Table  S5) . This tumor, which also belonged to the C1A (SDH-related) expression cluster was a local recurrence of an adrenal pheochromocytoma resected from a 63-year-old female presenting a high level of urinary normetanephrines. To explain this ''SDHlike'' phenotype, we performed the whole-exome sequencing of tumor and matched blood DNA. We identified 21 nonsynonymous somatic mutations effecting exons or splice sites in this tumor, 16 of which were predicted to have functional consequences (Table S10 ). In particular, a somatic mutation was identified in exon 7 of the fumarate hydratase (FH) gene (c.1043G > C, p.Gly348Ala). This patient also carried a germline mutation in exon 3 of FH (c.349G > C, p.Ala117Pro). Both mutations were verified by Sanger sequencing ( Figure 5A ). The p.Ala117Pro mutation has been described previously in patients with multiple leiomyomatosis and/or renal cancer, displaying reduced FH activity. Interestingly, the patient's clinical record revealed that she had benefited from a total hysterectomy at 35 years old for between SdhbÀ/À and WT imCCs along the y axis and the CpG island methylation difference between SDHx-related PGL/PCC and other tumors along the x axis. Genes significantly hypermethylated in both human tumors and mouse chromaffin cells are indicated in red.
(G) Cell migration is shown in a wound scratch assay after 10 hr, in standard medium or following 72 hr of DAC treatment at 10 nM or 5 mM. Scale bar = 100 mm.
(H) Reversion of the migratory phenotype by decitabine treatment. Data are mean ± SEM. See also Figure S2 and Table S3 . hemorrhagic fibromas. The p.Gly348Ala mutation has not been described previously and was predicted to be ''probably damaging'' by Polyphen software. Tumor HS_121 displayed a selective loss of FH activity ( Figure 5B ), accompanied by an increase in fumarate concentrations ( Figure 5C ). Fumarate, like succinate, is a competitive inhibitor of 2-OG-dependent dioxygenases (Xiao et al., 2012) , so these findings strongly suggest that FH inactivation causes PGL/PCC by establishing a hypermethylator phenotype.
DNA Hypermethylation and Associated Gene Silencing
Are Stronger in SDHB-Mutated Tumors SDHB-mutated PGL/PCC tend to be more malignant than tumors harboring mutations in other SDH subunits (Amar et al., 2005; Pasini and Stratakis, 2009 ). To determine whether this aggressive behavior is associated with a more severe hypermethylator phenotype, we calculated the mean methylation level across all the CpG sites significantly hypermethylated in Figure S4 and Tables S6, S7 , S8, and S9.
M1 tumors and located within CpG islands. This methylation level was, as expected, higher in all M1 tumors than in M2 and M3 tumors ( Figure 6A) ; but, SDHB-mutated tumors displayed stronger hypermethylation than other M1 tumors (1 SDHA-, 1 SDHC-, 3 SDHD-, and 1 FH-mutated tumors) (p = 0.0071). We examined the transcriptional consequences of these differences by calculating the mean expression level of the 191 genes significantly hypermethylated and downregulated in M1 tumors (Table S8) . Although these genes were downregulated in all M1 tumors as compared to M2 and M3 tumors, their expression was significantly lower in SDHBmutated tumors than in other M1 tumors (p = 0.0055, Figure 6B) . The levels of hypermethylation and downregulation of target genes were highly correlated (Pearson's r = À0.93, p = 7.0 3 10 À59 ; Figure 6C ), suggesting that DNA methylation finely regulates the expression of these genes in PGL/PCC. These findings support the idea that a stronger hypermethylator phenotype, associated with a stronger downregulation of target genes, may participate to the metastatic phenotype of SDHBmutated tumors.
Cancer Cell
Hypermethylator Phenotype in SDH-Related PGL/PCC
Comparison with the CpG Island Methylator Phenotypes Identified in Colorectal Cancer and Glioblastoma
We investigated whether the hypermethylator phenotype identified in PGL/PCC showed similarities with previously described CIMP phenotypes. We analyzed publicly available data concerning colorectal cancers (Hinoue et al., 2012) and glioblastomas (Noushmehr et al., 2010) , obtained with the same Illumina Infinium HM27 methylation array used in this study. For each CpG site, we calculated the mean beta value difference between tumors with and without a hypermethylator phenotype (CIMPhigh in colorectal cancer, G-CIMP in glioblastoma). Although we found a significant overlap between hypermethylated loci in the three cancers, the patterns of hypermethylation were particularly similar between PGL/PCC and G-CIMP glioblastomas ( Figure 7A ). Of 2,241 CpG sites hypermethylated in PGL/PCC of the M1 subgroup (mean beta value difference >0.2 as compared to non-M1 tumors), 847 (38%) were also hypermethylated in G-CIMP glioblastomas, whereas only 279 (12%) were hypermethylated in CIMP-high-colorectal tumors ( Figure 7B ). Gene set enrichment analysis (GSEA) confirmed that the set of genes hypermethylated in PGL/PCC was more significantly enriched in genes hypermethylated in G-CIMP glioblastomas (enrichment score = 0.75) than genes hypermethylated in CIMP-high-colorectal cancers (enrichment score = 0.47) (Figure S5) . Seventeen of the 191 genes epigenetically silenced in PGL/PCC were significantly hypermethylated and downregulated in glioblastoma (including PNMT and RBP1); 21 were hypermethylated but without significant downregulation (like KRT19); and 119, like NPY, were not found to be hypermethylated in glioblastoma (Table S8 ). The similarity between PGL/ PCC and glioblastoma hypermethylator phenotypes may reflect the preferential activities of the 2-OG-dependent demethylases inhibited in these two cancers.
DISCUSSION
Metabolic reprogramming in cancer has long been regarded as an indirect response to cell proliferation, but recent evidence has shown that metabolites themselves can be oncogenic by altering several cellular processes (Ward and Thompson, 2012) . The oncometabolite 2-HG, produced by mutated IDH enzymes, establishes the G-CIMP phenotype in glioma by inhibiting DNA and histone demethylases (Xu et al., 2011) . Succinate and fumarate can activate the oncogenic HIF pathway by inhibiting HIF prolyl-hydroxylases (Briè re et al., Selak et al., 2005) . Here, we demonstrate that succinate accumulation in SDH-deficient PGL/PCC establishes a hypermethylator phenotype, by inhibiting 2-OG-dependent oxidative demethylation. Besides, we describe a specific model of SDH-related PGL/ PCC, generated by knocking out Sdhb gene in chromaffin cells. In the past, the lack of an appropriate cellular model has opposed severe limitations to the understanding of SDH-related oncogenesis. Our model displays a complete inactivation of SDH activity, which cannot be achieved by siRNA-mediated gene silencing, and will be a crucial tool for deciphering the consequences of SDH inactivation in these cells. Our study also led to the identification of a case of FH germline mutation in an apparently sporadic PCC displaying a hypermethylator phenotype. FH mutations are known to predispose to hereditary leiomyomatosis and renal cell cancer (Tomlinson et al., 2002 ) but have never been described in PGL/PCC. Altogether, these findings shed light on a novel pathway explaining the tumor-suppressive role of SDH and FH and, echoing the role of IDH mutation in glioma, emphasize the link between TCA cycle dysfunction and epigenomic alterations in cancer. Gastrointestinal stromal tumors, renal cancer, and leiomyomas harboring SDH or FH mutations may also display epigenetic reprogramming, which should be assessed in future DNA methylation studies. Many cancer-specific hypermethylation events occur in promoter regions of genes that are not normally expressed and are therefore not affected by DNA methylation changes (Widschwendter et al., 2007) . To distinguish DNA methylation events of potential functional significance (''driver events'') from these ''passenger events'', we integrated the DNA methylation data with gene expression profiles of the same tumors. Only 11.5% of genes with significant promoter hypermethylation in PGL/ PCC of the M1 subgroup were underexpressed in these tumors. This is consistent with previous reports in colorectal cancer (7.3%; Hinoue et al., 2012) and glioblastoma (17%; Noushmehr (B) Enzymatic activity, assayed spectrophotometrically for the forward (fumarate to malate, left traces) and backward (malate to fumarate, right traces) directions, reveals a severe fumarase deficiency in HS_121 (red) relative to control (black) PGL/PCC samples. (C) Loss of fumarase activity is associated with a higher fumarate concentration in tumor HS_121 than that in control PGL/PCC (n = 6). For controls, data are mean ± SEM. See also Table S10. et al., 2010). Thus, most hypermethylated CpG sites appear to be silent consequences of the inhibition of DNA demethylases, with no evident functional impact. We were however able to show an overall correlation between the level of hypermethylation and downregulation of gene expression. In particular, we identified 191 genes that showed significant hypermethylation and downregulation in M1 tumors and whose expression was closely correlated with the degree of DNA methylation.
Two of the genes showing the strongest evidence for epigenetic silencing in hypermethylated PGL/PCC are, respectively, involved in the differentiation of chromaffin cells (PNMT; Eisenhofer et al., 2011) and the epithelial-to-mesenchymal transition (KRT19; Moreno-Bueno et al., 2006) , which was recently identified as the first mechanistic clue to explain the particularly invasive phenotype of SDHB-related tumors (Loriot et al., 2012) . The PNMT gene encodes the phenyl-ethanolamine-N-methyltransferase, a key enzyme of chromaffin cell metabolism, which catalyzes the conversion of noradrenaline to adrenaline. Reduced PNMT expression has been reported in SDH-related tumors, leading to an immature catecholamine secretory profile with predominant secretion of noradrenaline or dopamine (Burnichon et al., 2012b; Eisenhofer et al., 2001 ). Our findings reveal that PNMT is hypermethylated in SDH-related tumors, together with four other genes implicated in catecholamine metabolism (DRD2, SULT1A1, SLC6A2, and NPY). Epigenetic regulation is thus a previously unsuspected mechanism explaining the dedifferentiated phenotype of this subgroup of PGL/PCC. Another target of the PGL/PCC hypermethylator phenotype, RBP1, is also epigenetically silenced in G-CIMP gliomas (Noushmehr et al., 2010) and several cancer cell lines and primary tumors (Esteller et al., 2002) . RBP1 is involved in retinoic acid signaling, leading to loss of cell differentiation and tumor progression (Farias et al., 2005) and may thus have a tumor-suppressive role in PGL/PCC. Studies aimed at elucidating the functional consequences of epigenetic gene silencing will undoubtedly improve our understanding of the role of DNA hypermethylation in PGL/PCC tumorigenesis.
SDH-and VHL-related tumors were previously shown to have similar gene expression features, like the activation of hypoxiarelated genes (Dahia et al., 2005) . In the COMETE cohort, we showed that, although close, these tumors were classified in two separate gene expression clusters (C1A and C1B) (Burnichon et al., 2011) . Here, we found that 150 out of 344 genes (44%) significantly downregulated in SDH-as compared to VHL-tumors were hypermethylated (data not shown). Epigenetic remodeling thus explains a significant part of transcriptional differences between SDH-and VHL-related tumors.
SDHB mutations confer a much worse prognosis than mutations in other SDHx genes (Amar et al., 2007) . No mechanism has been proposed to explain these differences. We found that although all SDHx-mutated tumors displayed a hypermethylator phenotype, the level of hypermethylation was significantly higher, and the expression of target genes was significantly lower in SDHB-mutated tumors. As target genes include genes implicated in neuroendocrine differentiation and epithelial-to-mesenchymal transition (EMT), this may explain the particular malignancy of SDHB-mutated tumors. SDHB encodes a catalytic subunit of SDH (Rutter et al., 2010) . We hypothesize that SDH inactivation may be more complete in SDHB-mutated tumors than in tumors harboring mutations in other subunits, leading to a higher succinate accumulation and hence to a stronger inhibition of 2-OG-dependent demethylation. However, we were not able to detect significant differences in succinate concentrations between SDHB-mutated and other SDH-related tumors. Future studies will be needed to dissect the functional impact of mutations affecting different SDH subunits.
There have recently been several promising findings for epigenetic cancer therapy. Notably, Tsai et al. (2012) demonstrated that low doses of the DNA demethylating agents, DAC and azacitidine, had durable antitumor effects on hematological and epithelial tumor cells. Thus, low doses may help avoid the extreme toxicities of these agents at high dose that have prevented the investigation of the true clinical responses. We show 
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Hypermethylator Phenotype in SDH-Related PGL/PCC that the increased migratory capacities of SdhbÀ/À mouse chromaffin cells are repressed by transient DAC treatment, even at a 10 nM concentration, which led to minor cytotoxicity. The precise molecular changes associated with these treatments will have to be deciphered in future studies, both in vitro and in vivo. In view of these findings, the reversal of promoter DNA hypermethylation and associated gene silencing may rise as an attractive alternative approach to surgery for SDHx-and FH-mutated PGL/PCC. NPY, which shows the strongest transcriptional silencing in M1 tumors, may be a good marker. NPY levels were shown to be increased in the plasma and tumors of patients with PCC and to be significantly lower in extra-adrenal tumors (deS Senanayake et al., 1995) . A comprehensive study of candidate markers in a large independent cohort will be useful to determine the best marker of this aggressive subgroup.
In summary, our analysis indicates that PGL/PCC can be classified into three distinct subgroups according to genome-scale DNA methylation changes. The identification of a hypermethylator phenotype in SDHx-and FH-mutated tumors helps in explaining both the tumor-suppressive role of these genes and some of the phenotypic characteristics of these tumors. The malignancy of SDHB-mutated PGL/PCC may be due to a severe epigenetic silencing of genes involved in cell differentiation and EMT. These findings have clinical implications for PGL/PCC diagnosis and may lead to targeted epigenetic treatment for patients with TCA cycle alterations. (CPP Paris-Cochin, January 2007). All patients provided written informed consent for the collection of samples and subsequent analyzes. Three adrenal medulla samples from healthy individuals were also included as controls. Germline DNA was extracted from leukocytes using standard protocols. Tumor and normal medulla samples were powdered in liquid nitrogen (30-50 mg), and DNA was extracted using a QIAamp DNA Mini Kit or an AllPrep Kit (QIAGEN, Hilden, Germany). For details, see the Supplemental Experimental Procedures.
DNA Methylation Arrays
Whole-genome DNA methylation was analyzed in 145 PGL or PCC and three normal adrenal medulla samples using the Illumina Infinium HumanMethylation27 assay (Bibikova et al., 2009 ). Twenty-four samples were later reanalyzed using the more comprehensive Illumina Infinium HumanMethylation450 Beadchips. Microarray experiments were performed by Integragen SA (Evry, France). In brief, genomic DNA was bisulfite-converted using the EZ-96 DNA Methylation Kit (Zymo Research, Irvine, CA, USA), whole-genome amplified, enzymatically fragmented, and hybridized to the BeadChip arrays in accordance with the manufacturer's instructions. The beta value DNA methylation scores for each locus were extracted together with detection p values from Illumina GenomeStudio software. As described elsewhere (Hinoue et al., 2012) , we replaced data points with a detection p value >0.05 by ''NA'' values, and we masked data points as ''NA'' for 4,484 probes that contain singlenucleotide polymorphisms or overlap with a repetitive element that are not uniquely aligned to the human genome (NCBI build 36/Hg18) or that overlap with regions of insertions and deletions in the human genome. Probes were considered to be in a promoter CpG island if they were located within a CpG island (UCSC database) and less than 1,500 bp away from a transcription start site.
DNA Methylation-Based Classification of Pheochromocytomas and Paragangliomas
We used consensus clustering (Monti et al., 2003) to identify PGL/PCC subgroups on the basis of their DNA methylation profiles. We selected the 10% most variant probes (n = 2,152) among those that did not contain any «NA»-masked data point. We then established consensus partitions of the data set in K clusters (for K = 2, 3, ., 8), based on 1,000 resampling iterations of hierarchical clustering, with Pearson's dissimilarity as the distance metric and Ward's method for linkage analysis. We used the cumulative distribution functions (CDF) of the consensus matrices to determine the optimal number of clusters, considering both the shape of the functions and the area under the CDF curves ( Figure S1 ). The Bioconductor ConsensusClusterPlus package was used for consensus clustering analysis.
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Reduced Representation Bisulphite Sequencing Analysis of Mouse Chromaffin Cells RRBS was performed by Integragen SA (Evry, France), as described elsewhere (Gu et al., 2011; Smallwood and Kelsey, 2012) . In brief, 300 ng of mouse genomic DNA were digested with 14 units of MspI (NEB). After end-repair, A-tailing, and ligation to methylated Illumina adapters, the library fragments of 40-220 bp were gel isolated, subjected to a double bisulfite conversion with the EpiTect Bisulfite kit from QIAGEN, PCR amplified, and sequenced on an Illumina HiSeq2000 sequencer as paired-end 75 bp reads. We used Trim Galore! (http://www.bioinformatics.babraham.ac.uk/projects/ trim_galore) to filter out the adaptor sequences. Bisulfite mapping and methylation calling were performed in a single step using the bismark software (Krueger and Andrews, 2011) . Only reads uniquely aligned to the mm9 assembly of the mouse genome were retained, and we required a coverage of at least ten reads to call methylation score for a CpG site. We downloaded the list of Mouse CpG islands from the UCSC genome browser, and we inferred a DNA methylation rate to each CpG island with more than ten individual CpG measurements and more than 100 total reads. To identify differentially methylated CpG sites or CpG islands, we compared the number of methylated and unmethylated observations in WT and SdhbÀ/À cells using Fisher's exact test. CpG islands with an FDR-adjusted p value <0.05 and absolute methylation difference >5% were considered differentially methylated. Human and mouse orthologs were downloaded from the Mouse Genome Database (Eppig et al., 2012) .
Generation of Sdhb-/-Immortalized Mouse Chromaffin Cells
Sdhb-floxed mice were generated at the Mouse Clinical Institute (Illkrich, France). A targeting vector containing Sdhb exon 2 flanked by LoxP sites followed by a neomycin (neo) selection cassette flanked by Frt sites (Figure 2A) was introduced into P1 (129 S2/SvPas) ES cells by electroporation. Two positive embryonic stem clones were injected into C57BL/6J blastocysts, and the resulting male chimeras gave germline transmission. These mice were mated to Flipase-expressing mice to delete the Neo cassette. Sdhb +/lox mice were intercrossed to obtain Sdhb lox/lox mice, and mouse chromaffin cells (mCCs) were isolated from the adrenal medulla of these Sdhb lox/lox as described elsewhere (Kolski-Andreaco et al., 2007) . All studies were performed in accordance with the relevant guidelines of the French Ministry of Agriculture (Authorization Executive Order A751532) for scientific experimentation on animals, European Communities Council Directive, and international ethical standards. Cells were cultured at 37 C, under 5% CO 2 in a standard medium containing Dulbecco's modified Eagle's medium with glutamine and a high glucose concentration (DMEM glutaMAX, GIBCO, Life Technologies, Saint Aubin, France) supplemented with 10% fetal bovine serum (GIBCO) and 1% penicillin-streptomycin (GIBCO). The cultures remained quiescent for 6 months, after which some started to grow spontaneously from mCCs clusters. These immortalized cells were isolated and infected with 10 7 plaque-forming units (pfu)/ml of an adenovirus expressing Cre-recombinase (Ad5CMV-Cre, Cell BioLabs, San Diego). A clonal approach by limiting dilution cloning assay was used to obtain homogenous Sdhb ÀÀ immortalized mCCs clones (imCC clones 6 and 8). Sdhb
and Sdhb lox/lox (referred to as WT) imCCs were maintained in standard medium with or without 2.5 mM dimethyl 2-oxoglutarate (Sigma-Aldrich, St. Louis).
ACCESSION NUMBERS
Methylation array data from the 148 human samples and RRBS data from the four mouse cell lines analyzed in this study have been deposited in NCBI's Gene Expression Omnibus (http://www.ncbi.nlm.nih. gov/geo) and are accessible through the GEO series accession number GSE43298. 
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